Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96SE0

UPID:
ABHD1_HUMAN

ALTERNATIVE NAMES:
Alpha/beta hydrolase domain-containing protein 1; Lung alpha/beta hydrolase 1

ALTERNATIVE UPACC:
Q96SE0; B3KSF6; E9PDR9; Q05BY3; Q53SZ1; Q8IXQ7

BACKGROUND:
The Protein ABHD1, alternatively named Alpha/beta hydrolase domain-containing protein 1 or Lung alpha/beta hydrolase 1, is integral to cellular function. Its alpha/beta hydrolase domain indicates a pivotal role in the hydrolysis of various biological molecules, contributing to cellular homeostasis. The protein's specific activities and interaction partners remain subjects of ongoing research, underscoring its importance in cellular metabolism.

THERAPEUTIC SIGNIFICANCE:
The exploration of Protein ABHD1's function is key to unlocking potential therapeutic applications. Although its association with specific diseases has not been identified, the protein's role in metabolic processes positions it as a candidate for therapeutic intervention. Future research into ABHD1 could reveal critical insights into metabolic diseases, paving the way for innovative treatment options.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.